Together, we can transform the future of lung cancer care
Lung cancer is the leading cause of cancer deaths in the United States and worldwide. At MSK, lung cancer researchers and clinical experts work together to develop innovative new treatments and provide best-in-class care, improving outcomes for people with lung cancer. Donor support helps make this possible.
Your support fuels breakthroughs
Thanks to donors, MSK is a leader in lung cancer research and care. U.S. News & World Report ranked MSK the #2 cancer hospital in the country, and Charity Navigator gave us its highest rating.
We’ve made considerable progress in lung cancer research
Donor contributions have been essential to MSK’s advancements in lung cancer. The establishment of the Fiona and Stanley Druckenmiller Center for Lung Cancer Research has given rise to many life-changing discoveries:
- A team of lung cancer experts at MSK identified a new rare type of lung cancer and its genetic drivers.
- MSK research and clinical trials have led to the development and approval of numerous treatments for many types of lung cancer, including a potential new treatment for patients with a specific type of KRAS mutation.
And we’re creating even more hope for tomorrow
Thanks to continued support from the MSK Giving community, even more breakthroughs are on the horizon:
- MSK thoracic surgeon Gaetano Rocco, MD, is testing a promising tool called an E-nose that can analyze a person’s breath to detect lung cancer.
- A new type of immunotherapy called tumor-infiltrating lymphocyte therapy has shown potential for being effective in treating non-small cell lung cancer.
- Understanding the link between a pregnancy-related protein and lung cancer outcomes.
Fund the next discovery in lung cancer research and care. You can also donate in honor or memory of a loved one.
Every donor gift is a gift of hope
Your gift today can power the next big breakthrough
With your support, MSK can continue leading the way in lung cancer research and care. Learn more about MSK’s innovations and advances and the progress you fuel as an MSK Giving donor.
Accelerating innovation
Established with a $40 million gift from MSK Board member Stanley Druckenmiller and his wife, Fiona, the Fiona and Stanley Druckenmiller Center for Lung Cancer Research at MSK is a multidisciplinary hub for therapeutic innovation.
Learn more about the centerAnswering the biggest questions
Thoracic oncologist and early drug development specialist Helena Yu, MD, is leading research to understand why lung cancer rates in younger nonsmoking women are not decreasing as rapidly as other demographics.
Read about the researchSupporting survivorship
Thanks to advances in lung cancer diagnosis and care, more people are living longer beyond their treatment. Philanthropy supports MSK’s survivorship programs, ensuring people with lung cancer get the follow-up care they need.
Learn moreDemystifying metastasis
Metastasis is the leading cause of cancer death and is present in over 50% of people diagnosed with lung cancer. MSK researchers have made many discoveries in this area, guiding the way toward new and better treatments.
See the discoveriesPioneering radiosurgery
MSK is running multiple clinical trials for stereotactic radiosurgery (SRS) for people whose lung cancer has spread to their brain. Combining advanced imaging with targeted radiation, SRS has fewer side effects than standard radiation.
Read moreTransform the future of lung cancer care worldwide.
